A GENE FEATURE ENUMERATION APPROACH FOR DESCRIBING HLA ALLELE POLYMORPHISM

Author:

Steven J. Mack

Author Affiliation:

Children's Hospital Oakland Research Institute
5700 Martin Luther King Jr. Way
Oakland, CA 94609, USA

Corresponding Author:

Steven J. Mack
SJMACK@CHORI.ORG

Short Title:

Gene Feature Enumeration for HLA Polymorphism

Keywords:

HLA; Nomenclature; Gene Feature Enumeration; Next Generation Sequencing; IHIW; 17th Workshop

Abbreviations:

ARD: Antigen Recognition Domain
EMLB: European Molecular Biology Laboratory
GF: Gene Feature
GFE: Gene Feature Enumeration
HLA: Human Leucocyte Antigen
IHIW: International HLA and Immunogenetics Workshop
IMGT: ImMunoGeneTics
NGS: Next Generation Sequencing
UTR: Untranslated Region

ABSTRACT

HLA genotyping via next generation sequencing (NGS) poses challenges for the use of HLA allele names to analyze and discuss sequence polymorphism. NGS will identify many new synonymous and non-coding HLA sequence variants. Allele names identify the types of nucleotide polymorphism that define an allele (non-synonymous, synonymous and non-coding changes), but do not describe how polymorphism is distributed among the individual features (the flanking untranslated regions, exons and introns) of a gene. Further, HLA alleles cannot be named in the absence of antigen-recognition domain (ARD) encoding exons. Here, a system for describing HLA polymorphism in terms of HLA gene features (GFs) is proposed. This system enumerates the unique nucleotide sequences for each GF in an HLA gene, and records these in a GF enumeration notation that allows both more granular dissection of allele-level HLA polymorphism, and the discussion and analysis of GFs in the absence of ARD-encoding exon sequences.

1. Introduction

The human leucocyte antigen (HLA) genes are well known as the most polymorphic loci in the human genome. The extensive sequence polymorphism known for the HLA alleles is curated by the ImMunoGeneTics (IMGT)/HLA Database[1], which annotates the individual features for each gene [nucleotide sequences of each exon, intron and flanking untranslated region (UTR)] and gene product (encoded protein sequences). Here, exons, introns and UTRs are collectively referred to as gene features (GFs) to distinguish them from “sequence features” described elsewhere [2].

The World Health Organization Nomenclature Committee for factors of the HLA system (HLA Nomenclature Committee) assigns a unique allele name to each unique HLA nucleotide sequence[3]. Each HLA allele name consists of four colon-delimited fields (e.g., *HLA-A*01:01:01:01*). The first field identifies the allele family (for all genes but *HLA-DPB1*); the second field enumerates the unique protein sequences for the alleles in a given allele family, in the order in which they were identified; the third field enumerates sequences with synonymous substitutions for a given protein sequence, in the order in which they were identified; and the fourth field enumerates sequences with nucleotide substitutions in UTRs and introns for a given synonymous sequence in an exon, in the order in which they were identified. *HLA-DPB1* lacks allele-families; the first field identifies unique protein sequences for all but the *DPB1*02* and **04* alleles, for which two distinct protein sequences each are known [3-5].

The IMGT/HLA Database is updated every three months, and the number of named HLA gene and pseudogene sequences increases with each update. For example, 9,946 HLA alleles had been named as of December of 2013[6]; this number increased to 12,242 in December of 2014[7], and 12,542 HLA alleles have been named as of January of 2015. Increases in the number of new allele sequences included in the database have followed the adoption of new genotyping technologies by the Histocompatibility and Immunogenetics (H&I) community, often in conjunction with international HLA and immunogenetics workshops (IHIWs).

The IMGT/HLA Database annotation, based on European Molecular Biology Laboratory (EMBL) formats, is available as hla.dat and hla.xml files from <ftp.ebi.ac.uk>. These files identify and characterize the nucleotide sequences corresponding to specific GFs for each HLA allele. As illustrated in Table 1, each HLA gene can have a different number of GFs, but all HLA genes have a 3' and 5' UTR, at least four exons and at least three introns. However, for most HLA genes, full-length sequence is unavailable for the majority of alleles. As illustrated in Figure 1, nucleotide sequences for more than 60% of HLA-A, -B, -C, and -DRB1 alleles in IMGT/HLA Database version 3.19.0 are available only for exons 2 and 3 of the class I genes, and exon 2 of the class II genes, as these exons encode the antigen recognition domain (ARD). Fewer than 6% of the alleles at these loci have full-length sequences, describing nucleotide sequence for all of an allele's GFs. Many of these full-length sequences have been generated using next generation sequencing (NGS) technologies, and the number of HLA alleles included in the database seems poised to increase dramatically as NGS technologies become widely used for HLA genotyping by H&I and genomics communities, and as part of the 17th IHIW.

1.1 Application of NGS Technology Highlights Current Nomenclature Limitations

The four colon-delimited field nomenclature for HLA alleles developed in step with genotyping technologies, as greater insights into the nature and scope of HLA polymorphism became available[4, 8-12]. While it provides insight into the *types* of polymorphism that distinguish alleles, this nomenclature does not identify the patterns and location of polymorphism across GFs at a given locus; the extent of the nucleotide sequence represented by an HLA allele name cannot be inferred from that name. The former issue has been partially addressed by extending allele names to identify those alleles that share

identical ARD-encoding exon sequences (G groups of alleles, e.g., *HLA-A*01:01:01G*), as well as those alleles that encode identical ARD protein sequences (P groups of alleles, e.g., *A*01:01P*)[3], as these GFs constitute the largest fraction of the database. However, outside of the G group extension, alleles that share nucleotide sequences for other GFs cannot easily be identified. For example, class I alleles that share identical sequences for one of the ARD-encoding exons, but not the other, cannot be identified using G groups.

The sequences of ARD-encoding exons are required for all nucleotide sequence submissions to the HLA Nomenclature Committee via IMGT/HLA Database, and novel nucleotide sequences for non-coding GFs must be submitted as part of full-length sequences. As a result, an HLA allele name cannot be assigned to a novel nucleotide sequence for an individual GF of interest (e.g., the 3' UTR of *HLA-C* [13, 14]) in the absence of nucleotide sequences for ARD-encoding GFs.

Klitz and Hedrick[15] have estimated that millions of alleles persist in the human population for each HLA gene. As NGS technologies extend sequence knowledge into non-ARD encoding GFs, the number of alleles distinguished by synonymous and non-coding variants can be expected to increase dramatically; for example, as illustrated in Table 1, introns 1 and 2 of class II genes can be several thousand nucleotides long, and are likely to have accumulated many nucleotide variants. These variants will be noted in the third and fourth fields of allele names, and it does not seem out of the case to imagine allele names like *HLA-DRB1*01:01:100:1004* in the near future. As the number of full-length HLA gene sequences generated increases, it seems likely that a large fraction of them will be unique.

Given the inability to determine which GFs are represented in an HLA allele name, the inability to assign allele names to individual non-ARD-encoding GFs, and the impending likelihood of a large number of unique full-length gene sequences, the utility of the HLA nomenclature is limited for managing, exchanging, discussing and analyzing nucleotide sequences for HLA GFs without the context of ARD-encoding GFs.

Here, a gene feature enumeration (GFE) notation is proposed as a supplement to the current HLA nomenclature for the purposes of cataloging nucleotide sequence polymorphisms for non-ARD-encoding GFs, discussing and analyzing HLA alleles in the context of polymorphism distributed between GFs, and capturing novel nucleotide sequences for non-ARD-encoding GFs generated via NGS technologies. This GFE approach is being developed as part of the 17th IHIWS Informatics Component.

2. Gene Feature Enumeration

HLA allele name nomenclature enumerates non-synonymous, synonymous and non-coding nucleotide variants in the second through fourth fields of an allele name. To supplement this approach, the unique sequences in each GF of a given HLA gene can be sequentially numbered, and applied to construct a second name for that allele consisting of one field for each GF, containing the unique number for that GF nucleotide sequence and delimited by colons for consistency with HLA nomenclature, prefaced with the allele name followed by a 'w' (for Workshop) to identify the provisional nature of this notation[16, 17]. This GFE notation is illustrated in Table 2.

For example, the *HLA-A* gene includes 17 GFs (Table 1); any *HLA-A* allele can be represented as a unique haplotype of 17 GFs. As illustrated in Table 2, and in Supplementary Table S1, *HLA-A*01:01:01:01* can be described in GFE notation as *HLA-Aw1:1:1:5:2:5:16:7:1:1:1:1:1:1:1:1:1*, identifying the constituent sequences of its GFs. In this case, the sequences for the *HLA-A*01:01:01:01* 5' UTR, exon 1, intron 1, and intron 5 through the 3' UTR are all the first sequences numbered for those *HLA-A* GFs. The nucleotide

**05:01:01:01*) share identical exon 4 sequences; that **02:01* and **03:01:01* share identical exon 3 sequences, as do **04:01:01* and **06:01:01*; and that **06:01:01* shares identical exon 1 sequence with four **04* alleles. In this respect, GFE is similar to the G group approach for identifying alleles with identical ARD-encoding GFs, but allows any combination of GFs to be compared. By identifying the relationship between alleles across all GFs, GFE notation facilitates the investigation of alleles that share, or are distinct at, non-ARD-encoding GFs.

In addition, GFE notation allows alleles that share particular GFs to be combined by converting the enumeration for other GFs to zeros. For example, *DQA1*04:01:01*, **04:01:02:01*, **04:01:02:02*, **04:02* and **06:01:01* can be identified as HLA-DQA1w0:7:0:0:0:0:0:0, as these alleles all share the same exon 1 nucleotide sequence. In this manner, alleles can be grouped for analysis by the variation at individual GFs, or selected GF sets, without having to parse the sequence information represented by the allele name. In this respect, GFE notation offers a solution to the potential problem of evaluating the significance of hypothetical alleles such as “HLA-DRB1*01:01:100:1004” and “HLA-DRB1*01:03:76:408”; using these allele names, the simple option for analysis would be to truncate them to two-field names (*HLA-DRB1*01:01* and **01:03*), ignoring any synonymous or non-coding variation. Using GFE notation, it may be possible to identify GFs that distinguish these alleles in terms of analytical significance.

Finally, GFE allows the consideration of nucleotide sequence variants in non-ARD-encoding GFs, and specifically in the absence of any non-ARD-encoding GF sequences. For example, if 3' UTR sequences are being studied, those 3' UTR sequences can be considered in the context of known polymorphism at a locus by using GFE notation that pertains to the 3' UTR only (e.g., HLA-DQA1w0:0:0:0:0:0:0:7 vs HLA-DQA1w0:0:0:0:0:0:0:10). GFE notation also allows for novel GF sequence variants to be compared with sequence variants that are already in the IMGT/HLA Database by assigning a new number to the novel variant. For example, the database includes 10 unique *HLA-DQA1* 3' UTR sequences; a novel *HLA-DQA1* 3' UTR can be named with GFE notation as HLA-DQA1w0:0:0:0:0:0:0:11 in the absence of exon 2 nucleotide sequences.

2.3 A Service for Managing Gene Feature Enumeration

GFE notation is not intended to replace HLA allele names; the long histories of HLA nomenclature and the H&I field, and the notoriety of specific HLA allele names preclude these names from ever being retired. GFE notation is proposed as a means for managing and discussing HLA polymorphism by acknowledging the underlying structure of the genes. As such, it is best managed in an automated fashion, with new GFE notations added as new HLA alleles are named, and updated as the nucleotide sequences of extant HLA allele names are extended to new GFs, with each IMGT/HLA Database release. An internet-based service would make GFE notations publically accessible, and would permit the automated inter-conversion of allele names and GFE notations. This service is under development as part of the 17th IHIW Informatics Component (ihiws.org/informatics-of-genomic-data/), and will be made available as an open-source product. Such a service could be applied to other highly polymorphic genetic systems.

Clearly, GF-level knowledge of the elements that distinguish alleles will be insufficient for many use cases. This service would serve a second function of characterizing the nucleotide polymorphisms that distinguish unique sequences for a given GF, fostering more granular investigations of HLA polymorphism.

The final function of this service would be to register novel, uncured HLA gene sequences generated by 17th IHIW NGS projects, and eventually by any HLA sequencing effort, prior to submission to the

IMGT/HLA Database, or for instances when ARD-encoding GF sequences are not available. Undoubtedly, many of the sequences so registered will result from sequencing errors, and should not be included in the IMGT/HLA Database. However, genuine novel nucleotide sequences may presumably be reported by multiple sequencing efforts, and this service would serve as a clearing house for such sequences.

3. Conclusions

Gene feature enumeration is a novel approach to describing HLA polymorphism that takes the structural elements of an HLA gene into account. This approach should be relatively easy to adopt, because it relies on information resources already provided by the IMGT/HLA Database. GFE notation will not supplant HLA allele names, but can complement them as the database accumulates sequences for non-ARD GFs generated via NGS methods. As knowledge of the regulatory roles of non-coding nucleotide sequences and their functional impacts on the HLA genes grows, it seems possible that the definition of an HLA allele may someday include promoters, enhancers and other intergenic sequences. GFE enumeration can accommodate this kind of growth in our understanding of immunogenetics in ways that allele names cannot. Given the inevitable changes that NGS methods will have on the H&I field, now is the time to discuss the best means of adapting to them.

Acknowledgements

This work was supported by National Institutes of Health (NIH) grants U01AI067068, awarded by the National Institute of Allergy and Infectious Disease (NIAID), and R01GM109030, awarded by the National Institute of General Medical Sciences (NIGMS). The content presented is solely the responsibility of the author and does not necessarily represent the official views of the NIH, NIAID, NIGMS or United States Government. The input of Henry Erlich, Marcelo Fernandez-Viña, Damian Goodridge and Martin Maiers is very much appreciated in the development of this work.

Literature Cited

1. Robinson, J., et al., *The IPD and IMGT/HLA database: allele variant databases*. Nucleic Acids Res, 2015. **43**(Database issue): p. D423-31.
2. Thomson, G., et al., *Sequence feature variant type (SFVT) analysis of the HLA genetic association in juvenile idiopathic arthritis*. Pac Symp Biocomput, 2010: p. 359-70.
3. Marsh, S.G., et al., *Nomenclature for factors of the HLA system, 2010*. Tissue Antigens, 2010. **75**(4): p. 291-455.
4. Marsh, S.G., et al., *Nomenclature for factors of the HLA system, 2002*. Hum Immunol, 2002. **63**(12): p. 1213-68.
5. Bodmer, J.G., et al., *Nomenclature for factors of the HLA system, 1989*. Tissue Antigens, 1990. **35**(1): p. 1-8.
6. Marsh, S.G., *Nomenclature for factors of the HLA system, update December 2013*. Tissue Antigens, 2014. **83**(3): p. 229-35.
7. Marsh, S.G., *Nomenclature for factors of the HLA system, update December 2014*. Hum Immunol, 2015. **24**(15): p. 00007-5.
8. Bodmer, W.F., et al., *Nomenclature for factors of the HLA system 1984*. Immunogenetics, 1984. **20**(6): p. 593-601.
9. *Nomenclature for factors of the HLA system, 1987*. Immunogenetics, 1988. **28**(6): p. 391-8.
10. Bodmer, J.G., et al., *Nomenclature for factors of the HLA system, 1990*. Hum Immunol, 1991. **31**(3): p. 186-94.
11. Bodmer, J.G., et al., *Nomenclature for factors of the HLA system, 1995*. Human Immunology, 1995. **41**: p. 149-164.
12. Bodmer, J.G., et al., *Nomenclature for factors of the HLA System, 1996*. Hum Immunol, 1997. **53**(1): p. 98-128.
13. McCutcheon, J.A., et al., *Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA*. J Exp Med, 1995. **181**(6): p. 2085-95.
14. Kulkarni, S., et al., *Differential microRNA regulation of HLA-C expression and its association with HIV control*. Nature, 2011. **472**(7344): p. 495-8.
15. Klitz, W., P. Hedrick, and E.J. Louis, *New reservoirs of HLA alleles: pools of rare variants enhance immune defense*. Trends Genet, 2012. **28**(10): p. 480-6.
16. *Nomenclature for factors of the HL-A system*. Bull World Health Organ, 1972. **47**(5): p. 659-62.
17. *Nomenclature for factors of the HLA system*. Bull World Health Organ, 1975. **52**(3): p. 261-5.

Figure Legends

Figure 1. Percentages of *HLA-A*, *-B*, *-C* and *-DRB1* Alleles with Nucleotide Sequences for Sets of Gene Features in IMGT/HLA Database Release Version 3.19.0

Each of the four panels details the percentage of alleles for which the nucleotide sequence of sets of gene features (GFs) is known at the *HLA-A*, *-B*, *-C*, or *-DRB1* locus. Grey boxes represent GFs for which nucleotide sequence is known for a given percentage of alleles that locus.

The % Total value at the bottom of each column represents the percentage of alleles for which nucleotide sequence for each individual GF is known. Each % Total value in the second column represents the percentage of alleles for which nucleotide sequence for the GFs shown in grey in that row are known.

The total number of alleles at each locus is shown at the bottom of the first column.

Table 1. Maximum Lengths of Gene Features in 11 HLA Genes in IMGT/HLA Database Release 3.19.0

Locus	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	Intron 4	Exon 5	Intron 5	Exon 6	Intron 6	Exon 7	Intron 7	Exon 8	3' UTR
HLA-A	300	73	130	293	242	314	600	280	102	117	442	33	142	48	169		300
HLA-B	284	73	129	272	250	281	575	277	104	120	441	33	107	44			364
HLA-C	283	73	130	274	250	297	587	277	124	138	440	33	107	48	164		171
HLA-DPA1	523	100	3584	246	340	282	214	155									4331
HLA-DPB1	366	100	4536	264	4014	282	547	111	329	20							963
HLA-DQA1	746	82	3858	249	445	282	429	155									436
HLA-DQB1	530	109	1458	270	2889	291	517	111	485	24	611	14					206
HLA-DRB1	607	100	10306	272	3464	282	702	111	487	24	1142	14					325
HLA-DRB3	327	100	7681	270	2302	282	684	111	473	24	799	14					579
HLA-DRB4	313	100	9563	270	2741	282	704	111	474	24	302	14					570
HLA-DRB5		100		270		282		111		24		14					

The maximum length of the nucleotide sequences for each gene feature (GF) [untranslated region (UTR), exon or intron] for each HLA gene in 12,332 HLA alleles in IMGT/HLA Database release 3.19.0 is shown. Blank cells indicate that no GF exists for that gene. Values of 0 indicate that no sequences for that GF have been included in available IMGT/HLA Database annotations.

Table 2. Gene Feature Enumerations for Three *HLA-A* Alleles

IMGT/HLA Allele Name	Gene Feature Enumeration Notation	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	Intron 4	Exon 5	Intron 5	Exon 6	Intron 6	Exon 7	Intron 7	Exon 8	3' UT
<i>HLA-A*01:01:01:01</i>	HLA-Aw1:1:1:5:2:5:16:7:1:1:1:1:1:1:1:1	1	1	1	5	2	5	16	7	1	1	1	1	1	1	1	1	1
<i>HLA-A*01:01:01:02N</i>	HLA-Aw1.737:1:1:5:2.983:5:16:7:1:1:1:1:1:1:1.57	1.737	1	1	5	2.983	5	16	7	1	1	1	1	1	1	1	1	1.57
<i>HLA-A*01:01:02</i>	HLA-Aw0:0:0:5:0:6:0:0:0:0:0:0:0:0:0:0	0	0	0	5	0	6	0	0	0	0	0	0	0	0	0	0	0

For each *HLA-A* allele, the number assigned to each gene feature (GF) [flanking untranslated region (UTR), exon, or intron] represents a unique sequence for that GF, enumerated as described in section 2.1. GFs for which no sequence is available are assigned a value of 0. The GF enumeration (GFE) notation is a compilation of the enumerations for each GF, delimited with colons, and prefixed with the HLA gene name and the letter ‘w’. Decimal values identify fractional sequences for a given GF as described in section 2.1.

bioRxiv preprint doi: <https://doi.org/10.1101/015222>; this version posted February 15, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Table 3. Enumerated Gene Features for HLA-DQA1 in IMGT/HLA Database Release 3.19.0

IMGT/HLA Allele Name	Gene Feature Enumeration Notation	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	3' UTR
HLA-DQA1*01:01:01	HLA-DQA1w0:1:0:1:0:1:0:1:0	0	1	0	1	0	1	0	1	0
HLA-DQA1*01:01:02	HLA-DQA1w4:1:12:1:3:1:8:2:1	4	1	12	1	3	1	8	2	1
HLA-DQA1*01:02:01:01	HLA-DQA1w5:1:19:2:4:1:9:3:2	5	1	19	2	4	1	9	3	2
HLA-DQA1*01:02:01:02	HLA-DQA1w5:1:13:2:4:1:9:3:2	5	1	13	2	4	1	9	3	2
HLA-DQA1*01:02:01:03	HLA-DQA1w5:1:14:2:4:1:9:3:2	5	1	14	2	4	1	9	3	2
HLA-DQA1*01:02:01:04	HLA-DQA1w6:1:10:2:5:1:9:3:3	6	1	10	2	5	1	9	3	3
HLA-DQA1*01:02:02	HLA-DQA1w0:1:0:2:0:2:0:3:0	0	1	0	2	0	2	0	3	0
HLA-DQA1*01:02:03	HLA-DQA1w0:1:0:2:0:2:0:3:0	0	1	0	2	0	2	0	3	0
HLA-DQA1*01:02:04	HLA-DQA1w0:2:0:2:0:2:0:3:0	0	2	0	2	0	2	0	3	0
HLA-DQA1*01:03:01:01	HLA-DQA1w7:1:15:3:6:4:10:4:4	7	1	15	3	6	4	10	4	4
HLA-DQA1*01:03:01:02	HLA-DQA1w8:1:11:3:6:4:10:4:4	8	1	11	3	6	4	10	4	4
HLA-DQA1*01:04:01:01	HLA-DQA1w9:3:20:1:3:1:11:5:5	9	3	20	1	3	1	11	5	5
HLA-DQA1*01:04:01:02	HLA-DQA1w9:3:16:1:3:1:11:5:5	9	3	16	1	3	1	11	5	5
HLA-DQA1*01:04:02	HLA-DQA1w0:3:0:1:0:3:0:5:0	0	3	0	1	0	3	0	5	0
HLA-DQA1*01:05:01	HLA-DQA1w9:4:17:1:3:1:11:1:5	9	4	17	1	3	1	11	1	5
HLA-DQA1*01:05:02	HLA-DQA1w0:3:0:1:0:1:0:1:0	0	3	0	1	0	1	0	1	0
HLA-DQA1*01:06	HLA-DQA1w0:0:0:4:0:0:0:0:0	0	0	0	4	0	0	0	0	0
HLA-DQA1*01:07	HLA-DQA1w8.443:3:16:5:3:1:11:5:5.741	8.443	3	16	5	3	1	11	5	5.741
HLA-DQA1*01:08	HLA-DQA1w0:0:0:2:0:5:0:0:0	0	0	0	2	0	5	0	0	0
HLA-DQA1*01:09	HLA-DQA1w0:0:0:2:0:6:0:0:0	0	0	0	2	0	6	0	0	0
HLA-DQA1*01:10	HLA-DQA1w8.443:1:11:6:6:4:10:4:4.337	8.443	1	11	6	6	4	10	4	4.337
HLA-DQA1*01:11	HLA-DQA1w5.41:1:18:2:4:1:9:6:2.722	5.41	1	18	2	4	1	9	6	2.722
HLA-DQA1*01:12	HLA-DQA1w0:0:0:1:0:7:0:0:0	0	0	0	1	0	7	0	0	0
HLA-DQA1*02:01	HLA-DQA1w1:5:23:8:7:8:12:7:6	1	5	23	8	7	8	12	7	6
HLA-DQA1*03:01:01	HLA-DQA1w2:5:21:7:1:8:13:8:7	2	5	21	7	1	8	13	8	7
HLA-DQA1*03:02	HLA-DQA1w3:6:22:7:2:9:13:8:7	3	6	22	7	2	9	13	8	7
HLA-DQA1*03:03:01	HLA-DQA1w2:5:21:7:1:9:13:8:7	2	5	21	7	1	9	13	8	7
HLA-DQA1*03:03:02	HLA-DQA1w0:5:0:7:0:10:0:8:0	0	5	0	7	0	10	0	8	0
HLA-DQA1*04:01:01	HLA-DQA1w0:7:0:9:0:11:0:9:0	0	7	0	9	0	11	0	9	0
HLA-DQA1*04:01:02:01	HLA-DQA1w12.18:7:4:9:8:12:5:9:10.997	12.18	7	4	9	8	12	5	9	10.997
HLA-DQA1*04:01:02:02	HLA-DQA1w12.171:7:1:9:8:12:5:9:10.435	12.171	7	1	9	8	12	5	9	10.435
HLA-DQA1*04:02	HLA-DQA1w12:7:2:9:8:13:5:9:10.243	12	7	2	9	8	13	5	9	10.243
HLA-DQA1*04:03N	HLA-DQA1w0:0:0:10:0:0:0:0:0	0	0	0	10	0	0	0	0	0
HLA-DQA1*04:04	HLA-DQA1w0:0:0:9:0:14:0:0:0	0	0	0	9	0	14	0	0	0
HLA-DQA1*05:01:01:01	HLA-DQA1w2.025:8:6:11:9:15:6:9:9	2.025	8	6	11	9	15	6	9	9
HLA-DQA1*05:01:01:02	HLA-DQA1w10:8:7:11:10:15:6:9:9	10	8	7	11	10	15	6	9	9
HLA-DQA1*05:01:02	HLA-DQA1w0:1.159:0:15:0:0:0:0:0	0	1.159	0	15	0	0	0	0	0
HLA-DQA1*05:02	HLA-DQA1w0:0:0:17:0:0:0:0:0	0	0	0	17	0	0	0	0	0
HLA-DQA1*05:03	HLA-DQA1w10.45:8:8:11:10:16:6:9:9	10.45	8	8	11	10	16	6	9	9
HLA-DQA1*05:04	HLA-DQA1w0:0:0:12:0:0:0:0:0	0	0	0	12	0	0	0	0	0
HLA-DQA1*05:05:01:01	HLA-DQA1w11:9:9:11:11:17:2:10:8	11	9	9	11	11	17	2	10	8
HLA-DQA1*05:05:01:02	HLA-DQA1w11:9:9:11:11:17:1:10:8	11	9	9	11	11	17	1	10	8
HLA-DQA1*05:05:01:03	HLA-DQA1w11:9:5:11:11:17:4:10:9.554	11	9	5	11	11	17	4	10	9.554
HLA-DQA1*05:06	HLA-DQA1w0:8:0:11:0:18:0:9:0	0	8	0	11	0	18	0	9	0
HLA-DQA1*05:07	HLA-DQA1w0:8:0:11:0:16:0:11:0	0	8	0	11	0	16	0	11	0
HLA-DQA1*05:08	HLA-DQA1w0:9:0:11:0:19:0:10:0	0	9	0	11	0	19	0	10	0
HLA-DQA1*05:09	HLA-DQA1w0:10:0:11:0:17:0:10:0	0	10	0	11	0	17	0	10	0
HLA-DQA1*05:10	HLA-DQA1w0:0:0:13:0:17:0:0:0	0	0	0	13	0	17	0	0	0
HLA-DQA1*05:11	HLA-DQA1w11:9:9:11:11:17:3:12:8	11	9	9	11	11	17	3	12	8
HLA-DQA1*06:01:01	HLA-DQA1w12.208:7:3:14:12:11:7:9:10	12.208	7	3	14	12	11	7	9	10
HLA-DQA1*06:01:02	HLA-DQA1w0:0:0:16:0:1.004:0:0:0	0	0	0	16	0	1.004	0	0	0
HLA-DQA1*06:02	HLA-DQA1w0:0:0:14:0:20:0:0:0	0	0	0	14	0	20	0	0	0

Figure 1.

A. HLA-A

# Alleles	% Total	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	Intron 4	Exon 5	Intron 5	Exon 6	Intron 6	Exon 7	Intron 7	Exon 8	3' UTR
1913	63.87%																	
513	17.13%																	
212	7.08%																	
99	3.31%																	
85	2.84%																	
55	1.84%																	
40	1.34%																	
23	0.77%																	
17	0.57%																	
13	0.43%																	
10	0.33%																	
6	0.20%																	
5	0.17%																	
4	0.13%																	
2995	% Total	3.51%	17.06%	4.84%	100%	4.84%	100%	4.84%	35.79%	4.84%	16.83%	4.84%	9.32%	4.84%	9.32%	4.84%	9.02%	4.07%

B. HLA-B

# Alleles	% Total	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	Intron 4	Exon 5	Intron 5	Exon 6	Intron 6	Exon 7	3' UTR
2428	64.57%															
571	15.19%															
270	7.18%															
132	3.51%															
130	3.46%															
81	2.15%															
44	1.17%															
43	1.14%															
27	0.72%															
11	0.29%															
11	0.29%															
9	0.24%															
2	0.05%															
1	0.03%															
3760	% Total	3.70%	19.47%	5.19%	100%	5.16%	100%	5.16%	34.28%	5.16%	16.94%	5.16%	9.04%	5.16%	8.75%	3.75%

Figure 1. (Continued)

C. HLA-C

# Alleles	% Total	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	Intron 4	Exon 5	Intron 5	Exon 6	Intron 6	Exon 7	Intron 7	Exon 8	3' UTR
1788	70.04%																	
334	13.08%																	
146	5.72%																	
89	3.49%																	
42	1.65%																	
32	1.25%																	
26	1.02%																	
22	0.86%																	
18	0.71%																	
15	0.59%																	
14	0.55%																	
8	0.31%																	
8	0.31%																	
6	0.24%																	
2	0.08%																	
2	0.08%																	
1	0.04%																	
2553	% Total	6.07%	15.90%	7.48%	100%	7.48%	100%	7.48%	29.65%	7.48%	15.55%	7.48%	14.77%	7.48%	11.20%	7.48%	9.32%	6.31%

D. HLA-DRB1

# Alleles	% Total	5' UTR	Exon 1	Intron 1	Exon 2	Intron 2	Exon 3	Intron 3	Exon 4	Intron 4	Exon 5	Intron 5	Exon 6	3' UTR
1399	85.41%													
94	5.74%													
62	3.79%													
28	1.71%													
25	1.53%													
12	0.73%													
7	0.43%													
6	0.37%													
2	0.12%													
2	0.12%													
1	0.06%													
1638	% Total	1.65%	8.73%	1.65%	100%	1.65%	14.16%	1.65%	9.65%	1.65%	9.22%	1.65%	9.10%	1.53%